Our research focuses on enhancing antimicrobial drug discovery – covering aspects from early target validation to detailed characterisation studies of novel antimicrobial substances. We develop fast and predictive high-throughput screening (HTS) tools, for example, by using bacterial bioreporters, and use combinations of target- and cell-based approaches in our screening campaigns. Through collaborations, our expertise in screening technologies and assay development is also employed in other therapeutic areas. We place special emphasis on using natural products (NP) and NP-inspired synthetic compounds in screening to facilitate their integration into HTS campaigns.
We belong to the Drug Research Program and the Division of Pharmaceutical Biosciences at the Faculty of Pharmacy. We are also hosting the DDCB Screening Unit, which provides researchers access to screening instrumentation as well as consultation in matters such as compound libraries, screening assay development and quality control relevant for screening campaigns. This unit belongs to the Drug Discovery and Chemical Biology network, and is a HiLIFE infrastructure facility, and EU-OPENSCREEN partner site. Please visit the DDCB Pharmacy website for further information.